Abstract:Treating HIV is made difficult by the evolution of antimicrobial resistant mutants of that occurs in the life cycle of this virus. This has led to the evolution of numerous inhibition mechanism that intends to challenges the replication of this virus. One such approach is the application of molecular modelling in drug discovery. In this study the application of computer aided drug design were employed in finding an inhibitor that can contribute in finding a suitable drug candidate. Firstly, the ZINC database was screened using the Lipinski’s rule of five, and compounds having similar biological features were classified and grouped together into a compound library. Secondly, the co-crystallized structure of 1rv7 wild type of HIV-1 protease was used to construct a pharmacophore model that was used to screen further, the ZINC database Ligand stored in the compound library. Thestructure-basedpharmacophore was created by mimicking the three main active features of the co-crystallized structure from the Protein Data Bank, namely, 82 and 84, I50 and I150 residues.Thirdly, a total of twenty-six of the compounds that had less than 0,5 RMSD were identified and selected. Fourthly, based on the best docking ligands, ten of these compounds having high binding affinity were selected. These compounds are ZINC_001456687980 (-8.0), ZINC_001445792073 (-7.8) and ZINC_001461099137 (-7.4), successively. However, ZINC_001461099137 was eliminated based on unfavorable donor-donor interaction. The subsequent compound, ZINC_000015276352 was then placed on the top three leading compounds with a binding affinity of (-6.9). Fifthly, the ADMET property analysis was used on the top ten compounds, and the compounds that satisfied the analysis were, ZINC_001456687980, ZINC_000015276352, ZINC_001359888321 and ZINC_001460445290. The main properties that included the BBB permeation, the gastrointestinal absorption, pan assay interference structure (PAINS), were analyzed. ZINC_001456687980 had two violation (mw >350, XLOGP3>3.5),whiles ZINC_000015276352 had three violations (mw > 350, XLOGP3 > 3.5, rotatable > 7). Lastly, only two top compound underwent molecular dynamics simulations. Molecular dynamics simulation revealed the formation of numerous bond interactions between ZINC_001456687980 and ZINC_000015276352 together with the target protein.

Synthesis of a Long Acting HIV Protease Inhibitor Via Metal or Enzymatic Reduction of the Appropriate Chloro Ketone and Selective Zinc Enolate Condensation with an Amino Epoxide

An Efficient and Practical Synthesis of the HIV Protease Inhibitor Atazanavir Via a Highly Diastereoselective Reduction Approach

Rh(iii)-Catalyzed Diastereoselective Transfer Hydrogenation: an Efficient Entry to Key Intermediates of HIV Protease Inhibitors

Symmetrical Phosphinic Acids: Synthesis and Esterification Optimization toward Potential HIV Prodrugs

Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor.

Synthesis of (2S, 3S)-1,2-epoxy-3-(Boc-amino)-4-phenylbutane

Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives

An enzymatic route to the synthesis of tricyclic fused hexahydrofuranofuran P2-Ligand for a series of highly potent HIV-1 protease inhibitors

Redesign of a Short-Chain Dehydrogenase/reductase for Asymmetric Synthesis of Ethyl (R)-2-hydroxy-4-phenylbutanoate Based on Per-Residue Free Energy Decomposition and Sequence Conservatism Analysis

Synthetic Studies of an Analogue of Hiv-1 Protease Inhibitors of Didemnaketals: Construction of the C1-C8 Intermediate

Total Synthesis of Anti-Hiv Agent Chloropeptin I.

A Simple and Highly Efficient Preparation of Structurally Diverse Aryl Β-Diketoacids As HIV-1 Integrase Inhibitors

Identification of ZINC inhibitors for HIV-1 Protease through Structure-Based Pharmacophore, Virtual Screening, ADMET and Molecular Dynamics Simulation

Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase.

Design and Synthesis of Conformationally Constrained Inhibitors of Non-Nucleoside Reverse Transcriptase

Modular Total Chemical Synthesis of a Human Immunodeficiency Virus Type 1 Protease

Design, Synthesis and Evaluation of Novel HIV-1 NNRTIs with Dual Structural Conformations Targeting the Entrance Channel of the NNRTI Binding Pocket

Efficient Synthesis of the C1-C7 Fragment of Didemnaketal A

A convergent synthesis of the spiroketal moiety of the HIV-1 protease inhibitors didemnaketals

Identification of Spirocyclic or Phosphate Substituted Quinolizine Derivatives As Novel HIV-1 Integrase Inhibitors: a Patent Evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1

Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1 ligands